Ardelyx (ARDX) Return on Capital Employed (2014 - 2026)
Ardelyx (ARDX) posted Return on Capital Employed of 9.51% for Q1 2026, up 5.94% on a QoQ basis from 10.11% in Q4 2025, and up 190.0% year-over-year from 3.28% in Q1 2025.
Ardelyx (ARDX) Return on Capital Employed (2014 - 2026) Analysis & Trends
Ardelyx's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 9.51% for Q1 2026.
- Quarterly Return on Capital Employed rose 190.0% year-over-year to 9.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.51% (up 190.0% YoY) and the FY2025 annual result came in at 10.78%, down 110.0% from the prior year.
- Return on Capital Employed was 9.51% for Q1 2026 at Ardelyx, up from 10.11% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 8.63% in Q4 2024 and bottomed at 163.53% in Q1 2022.
- A 5-year average of 44.67% and a median of 22.46% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 10199 bps — and 2023, when it soared 12638 bps.
- Ardelyx's Return on Capital Employed stood at 62.65% in 2022, then soared by 58 bps to 26.03% in 2023, then jumped by 67 bps to 8.63% in 2024, then retreated by 17 bps to 10.11% in 2025, then climbed by 6 bps to 9.51% in 2026.
- Business Quant data shows ARDX's Return on Capital Employed at 9.51% in Q1 2026, 10.11% in Q4 2025, and 9.65% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | -9.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.51% |
| Dec 31, 2025 | -10.11% |
| Sep 30, 2025 | -9.65% |
| Jun 30, 2025 | -11.32% |
| Mar 31, 2025 | -11.41% |
| Dec 31, 2024 | -8.63% |
| Sep 30, 2024 | -22.46% |
| Jun 30, 2024 | -21.00% |
| Mar 31, 2024 | -23.52% |
| Dec 31, 2023 | -26.03% |
| Sep 30, 2023 | -11.19% |
| Jun 30, 2023 | -34.39% |
| Mar 31, 2023 | -44.15% |
| Dec 31, 2022 | -62.65% |
| Sep 30, 2022 | -128.99% |
| Jun 30, 2022 | -160.78% |
| Mar 31, 2022 | -163.53% |
| Dec 31, 2021 | -143.50% |
| Sep 30, 2021 | -123.14% |
| Jun 30, 2021 | -81.17% |